Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
 |
|
|
Open Access Green as soon as Postprint is submitted to ZB.
Longevity, aging and rapamycin.
Cell. Mol. Life Sci. 71, 4325-4346 (2014)
The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains. Here, we review what is currently known about the effects that pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition have on mammalian aging and longevity. Currently available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Aging ; Anti-aging ; Cancer ; Cardiovascular Disease ; Disease ; Drug ; Lifespan ; Longevity ; Mammalian Target Of Rapamycin ; Mammals ; Mechanism ; Mice ; Mtor ; Neurodegeneration ; Prevention ; Rapamycin ; Treatment
ISSN (print) / ISBN
1420-682X
e-ISSN
1420-9071
Quellenangaben
Volume: 71,
Issue: 22,
Pages: 4325-4346
Publisher
Birkhäuser
Non-patent literature
Publications
Reviewing status
Peer reviewed